429 related articles for article (PubMed ID: 34555287)
1. Asthma and COPD medicines prescription-claims: A time-series analysis of England's national prescriptions during the COVID-19 pandemic (Jan 2019 to Oct 2020).
Barrett R; Barrett R
Expert Rev Respir Med; 2021 Dec; 15(12):1605-1612. PubMed ID: 34555287
[TBL] [Abstract][Full Text] [Related]
2. Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England's prescription data during the COVID-19 pandemic (January 2019 to October 2020).
Barrett R; Hodgkinson J
Ther Adv Cardiovasc Dis; 2022; 16():17539447221137170. PubMed ID: 36420815
[TBL] [Abstract][Full Text] [Related]
3. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study.
Aveyard P; Gao M; Lindson N; Hartmann-Boyce J; Watkinson P; Young D; Coupland CAC; Tan PS; Clift AK; Harrison D; Gould DW; Pavord ID; Hippisley-Cox J
Lancet Respir Med; 2021 Aug; 9(8):909-923. PubMed ID: 33812494
[TBL] [Abstract][Full Text] [Related]
4. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
5. Prescription practices for chronic obstructive pulmonary disease: findings from the national ambulatory medical care survey 1999-2010.
Ford ES; Mannino DM; Giles WH; Wheaton AG; Liu Y; Croft JB
COPD; 2014 Jun; 11(3):247-55. PubMed ID: 24568285
[TBL] [Abstract][Full Text] [Related]
6. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
[TBL] [Abstract][Full Text] [Related]
7. Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset.
Barrett R; Barrett R; Lin SX; Culliford D; Fraser S; Edwards CJ
BMJ Open; 2022 Dec; 12(12):e051936. PubMed ID: 36564115
[TBL] [Abstract][Full Text] [Related]
8. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study.
Griffin J; Lee S; Caiado M; Kesten S; Price D
Prim Care Respir J; 2008 Jun; 17(2):104-10. PubMed ID: 18385913
[TBL] [Abstract][Full Text] [Related]
10. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease.
Cramer JA; Bradley-Kennedy C; Scalera A
Can Respir J; 2007; 14(1):25-9. PubMed ID: 17315055
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin inhibitors and related medicines: a cohort study examining England's primary care prescription changes during the COVID-19 pandemic (January 2019 to March 2021).
Barrett R
Daru; 2022 Jun; 30(1):59-66. PubMed ID: 35075618
[TBL] [Abstract][Full Text] [Related]
12. Prescribing Patterns and Treatment Adherence in Patients with Asthma During the COVID-19 Pandemic.
Dhruve H; d'Ancona G; Holmes S; Dhariwal J; Nanzer AM; Jackson DJ
J Allergy Clin Immunol Pract; 2022 Jan; 10(1):100-107.e2. PubMed ID: 34610490
[TBL] [Abstract][Full Text] [Related]
13. Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.
Lee TA; Schumock GT; Bartle B; Pickard AS
Pharmacotherapy; 2009 Sep; 29(9):1039-53. PubMed ID: 19698009
[TBL] [Abstract][Full Text] [Related]
14. Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma?
Ringbaek T; Viskum K
Respir Med; 2003 Mar; 97(3):264-72. PubMed ID: 12645834
[TBL] [Abstract][Full Text] [Related]
15. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
Norris V; Ambery C
Pulm Pharmacol Ther; 2013 Oct; 26(5):574-80. PubMed ID: 23524017
[TBL] [Abstract][Full Text] [Related]
16. Impact of abolishing prescription fees in Scotland on hospital admissions and prescribed medicines: an interrupted time series evaluation.
Williams AJ; Henley W; Frank J
BMJ Open; 2018 Dec; 8(12):e021318. PubMed ID: 30567818
[TBL] [Abstract][Full Text] [Related]
17. [Effects of salbutamol and ipratropium bromide on arterial blood gases in patients with stable COPD].
Ozdemir T; Geçkin E; Oğüş C; Cilli A
Tuberk Toraks; 2003; 51(2):132-7. PubMed ID: 15143418
[TBL] [Abstract][Full Text] [Related]
18. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
19. Medication prescribing for asthma and COPD: a register-based cross-sectional study in Swedish primary care.
Weidinger P; Nilsson JL; Lindblad U
BMC Fam Pract; 2014 Mar; 15():54. PubMed ID: 24666507
[TBL] [Abstract][Full Text] [Related]
20. Ipratropium treatment of acute airways disease.
Peterson GM; Boyles PJ; Bleasel MD; Vial JH
Ann Pharmacother; 2003 Mar; 37(3):339-44. PubMed ID: 12639159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
